MA53043A1 - Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation - Google Patents

Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Info

Publication number
MA53043A1
MA53043A1 MA53043A MA53043A MA53043A1 MA 53043 A1 MA53043 A1 MA 53043A1 MA 53043 A MA53043 A MA 53043A MA 53043 A MA53043 A MA 53043A MA 53043 A1 MA53043 A1 MA 53043A1
Authority
MA
Morocco
Prior art keywords
methods
thieno
udp
pyridine derivatives
derivatives used
Prior art date
Application number
MA53043A
Other languages
English (en)
Other versions
MA53043B2 (fr
Inventor
Bradford Hirth
Elina Makino
Mark Munson
Sachin Maniar
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
John JIANG
Yong-Mi Choi
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA53043A1 publication Critical patent/MA53043A1/fr
Publication of MA53043B2 publication Critical patent/MA53043B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i), tel que décrit ici, et des sels pharmaceutiquement acceptables de celui-ci. L'invention concerne également des compositions et l'utilisation de telles compositions dans des procédés de traitement de toute une série de maladies et d'états, en particulier la maladie de krabbe (mk) et la leucodystrophie métachromatique (mld).
MA53043A 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation MA53043B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (fr) 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA53043A1 true MA53043A1 (fr) 2022-08-31
MA53043B2 MA53043B2 (fr) 2024-05-31

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53043A MA53043B2 (fr) 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Country Status (15)

Country Link
US (1) US11098056B2 (fr)
EP (1) EP3861000A1 (fr)
JP (1) JP2022508523A (fr)
KR (1) KR20210087033A (fr)
CN (1) CN113423711B (fr)
AU (1) AU2019355870B2 (fr)
BR (1) BR112021005914A2 (fr)
CA (1) CA3114722A1 (fr)
CO (1) CO2021005738A2 (fr)
IL (1) IL281811A (fr)
MA (1) MA53043B2 (fr)
MX (1) MX2021003794A (fr)
SG (1) SG11202102987VA (fr)
TW (1) TWI821426B (fr)
WO (1) WO2020072504A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507222A (ja) * 2021-02-19 2024-02-16 カルビスタ・ファーマシューティカルズ・リミテッド 第ＸＩＩａ因子阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
AU6621600A (en) * 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
CA2703600C (fr) * 2007-11-15 2017-04-25 Ym Biosciences Australia Pty Ltd Composes heterocycliques de thieno ou pyrrolo pyrimidine fusionnes et leur utilisation comme inhibiteurs de jak1, jak2 ou jak3
SG173584A1 (en) * 2009-02-06 2011-09-29 Elan Pharm Inc Inhibitors of jun n-terminal kinase
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
ES2928714T3 (es) * 2015-01-16 2022-11-22 Massachusetts Gen Hospital Compuestos para mejorar el empalme del ARNm
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3468954A1 (fr) 2016-06-10 2019-04-17 BioMarin Pharmaceutical Inc. Inhibiteurs de la céramide galactosyltransférase pour le traitement de maladies
US20190322676A1 (en) 2016-12-20 2019-10-24 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MX2019013148A (es) * 2017-05-04 2019-12-18 Glenmark Pharmaceuticals Sa Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.
CA3066939A1 (fr) 2017-06-21 2018-12-27 SHY Therapeutics LLC Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques

Also Published As

Publication number Publication date
US11098056B2 (en) 2021-08-24
BR112021005914A2 (pt) 2021-06-29
TW202035419A (zh) 2020-10-01
US20200102324A1 (en) 2020-04-02
AU2019355870B2 (en) 2023-11-16
MA53043B2 (fr) 2024-05-31
JP2022508523A (ja) 2022-01-19
MX2021003794A (es) 2021-09-08
KR20210087033A (ko) 2021-07-09
CN113423711A (zh) 2021-09-21
CO2021005738A2 (es) 2021-05-10
SG11202102987VA (en) 2021-04-29
IL281811A (en) 2021-05-31
CA3114722A1 (fr) 2020-04-09
WO2020072504A1 (fr) 2020-04-09
EP3861000A1 (fr) 2021-08-11
CN113423711B (zh) 2024-03-15
TWI821426B (zh) 2023-11-11
AU2019355870A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA30412B1 (fr) Composés Pharmaceutiques
MA44674A (fr) Inhibiteurs de bromodomaine
MA49235A (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA46357B1 (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA37405A1 (fr) Composés hétérocyclyle
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
TNSN07022A1 (fr) Derives de pyridine
DE60103147D1 (de) 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation
MA29926B1 (fr) Derives de pyrazine
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires